These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 17204748)
1. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. Dhalla AK; Santikul M; Smith M; Wong MY; Shryock JC; Belardinelli L J Pharmacol Exp Ther; 2007 Apr; 321(1):327-33. PubMed ID: 17204748 [TBL] [Abstract][Full Text] [Related]
2. Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. Shearer J; Severson DL; Su L; Belardinelli L; Dhalla AK J Pharmacol Exp Ther; 2009 Jan; 328(1):306-11. PubMed ID: 18952888 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats. Dhalla AK; Santikul M; Chisholm JW; Belardinelli L; Reaven GM Diabetes Obes Metab; 2009 Feb; 11(2):95-101. PubMed ID: 18494808 [TBL] [Abstract][Full Text] [Related]
4. A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Dhalla AK; Wong MY; Voshol PJ; Belardinelli L; Reaven GM Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1358-63. PubMed ID: 17227958 [TBL] [Abstract][Full Text] [Related]
5. A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes. Fatholahi M; Xiang Y; Wu Y; Li Y; Wu L; Dhalla AK; Belardinelli L; Shryock JC J Pharmacol Exp Ther; 2006 May; 317(2):676-84. PubMed ID: 16410404 [TBL] [Abstract][Full Text] [Related]
6. N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside, an A1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats. Fraser H; Gao Z; Ozeck MJ; Belardinelli L J Pharmacol Exp Ther; 2003 Apr; 305(1):225-31. PubMed ID: 12649373 [TBL] [Abstract][Full Text] [Related]
7. Suppression of free fatty acids and triglycerides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladenosine. Hoffman BB; Dall'Aglio E; Hollenbeck C; Chang H; Reaven GM J Pharmacol Exp Ther; 1986 Dec; 239(3):715-8. PubMed ID: 3795036 [TBL] [Abstract][Full Text] [Related]
8. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats. van Schaick EA; Tukker HE; Roelen HC; IJzerman AP; Danhof M Br J Pharmacol; 1998 Jun; 124(3):607-18. PubMed ID: 9647488 [TBL] [Abstract][Full Text] [Related]
9. Modulation of insulin release by adenosine A1 receptor agonists and antagonists in INS-1 cells: the possible contribution of 86Rb+ efflux and 45Ca2+ uptake. Töpfer M; Burbiel CE; Müller CE; Knittel J; Verspohl EJ Cell Biochem Funct; 2008 Dec; 26(8):833-43. PubMed ID: 18979526 [TBL] [Abstract][Full Text] [Related]
10. The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans. Rigazio S; Lehto HR; Tuunanen H; Någren K; Kankaanpaa M; Simi C; Borra R; Naum AG; Parkkola R; Knuuti J; Nuutila P; Iozzo P Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E413-9. PubMed ID: 18505832 [TBL] [Abstract][Full Text] [Related]
11. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. Johansson SM; Lindgren E; Yang JN; Herling AW; Fredholm BB Eur J Pharmacol; 2008 Nov; 597(1-3):92-101. PubMed ID: 18789919 [TBL] [Abstract][Full Text] [Related]
12. Glucose-dependent insulin modulation of oscillatory lipolysis in perifused rat adipocytes. Getty-Kaushik L; Richard AM; Corkey BE Obes Res; 2005 Dec; 13(12):2058-65. PubMed ID: 16421338 [TBL] [Abstract][Full Text] [Related]
13. Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid. Johansson SM; Yang JN; Lindgren E; Fredholm BB Acta Physiol (Oxf); 2007 May; 190(1):87-96. PubMed ID: 17428236 [TBL] [Abstract][Full Text] [Related]
14. Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. van Schaick EA; Zuideveld KP; Tukker HE; Langemeijer MW; Ijzerman AP; Danhof M J Pharmacol Exp Ther; 1998 Oct; 287(1):21-30. PubMed ID: 9765317 [TBL] [Abstract][Full Text] [Related]
15. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. Van der Graaf PH; Van Schaick EA; Visser SA; De Greef HJ; Ijzerman AP; Danhof M J Pharmacol Exp Ther; 1999 Aug; 290(2):702-9. PubMed ID: 10411581 [TBL] [Abstract][Full Text] [Related]
16. A1 adenosine receptor: role in diabetes and obesity. Dhalla AK; Chisholm JW; Reaven GM; Belardinelli L Handb Exp Pharmacol; 2009; (193):271-95. PubMed ID: 19639285 [TBL] [Abstract][Full Text] [Related]